Last reviewed · How we verify
Interferon-Gamma
At a glance
| Generic name | Interferon-Gamma |
|---|---|
| Also known as | Ingaron, Interferon gamma human recombinant, Actimmune, immunotherapy, gamma interferon |
| Sponsor | SPP Pharmaclon Ltd. |
| Drug class | Lymphocyte Growth Factor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Fever
- Headache
- Rash
- Chills
- Injection site erythema or tenderness
- Fatigue
- Diarrhea
Serious adverse events
- Myocardial infarction
- Cardiac failure (including congestive cardiac failure)
- Pancreatitis with fatal outcome
- Stevens-Johnson syndrome
- Acute renal failure
- Pulmonary embolism
- Deep venous thrombosis
- Interstitial pneumonitis
- Convulsion/seizure (including grand mal convulsions)
- Gastrointestinal bleeding
Key clinical trials
- Training Protocol on the Natural History of Tuberculosis
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2, PHASE3)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (PHASE3)
- PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
- Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
- Evaluating the Safety and Immunogenicity of MTBVAC (PHASE2)
- Combining Epigenetic And Immune Therapy to Beat Cancer. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon-Gamma CI brief — competitive landscape report
- Interferon-Gamma updates RSS · CI watch RSS
- SPP Pharmaclon Ltd. portfolio CI